LivaNova wins CMS NTAP reimbursement for Perceval aortic valve

LivaNova (NSDQ:LIVN) said today that its Perceval sutureless aortic heart valve replacement won approval from the Centers for Medicare and Medicaid Services for a New Technology Add-On Payment.

The London-based company said that the Perceval valve had met the CMS criteria for the add-on payment, including showing substantial clinical improvement over existing technologies.

With the reimbursement approval, CMS will begin to reimburse hospitals for the Perceval valve procedure with the normal Medicare Severeity Diagnosis Related Group payment as well as an additional $6,110.23, LivaNova said.

“We are pleased CMS recognized the significant value of the Perceval valve in the management of aortic valve disease. Numerous publications in the medical literature have demonstrated the benefits of the Perceval valve compared to traditional surgical valves, and this decision will provide greater access to this important new technology. We look forward to continuing to provide the latest and most clinically beneficial technologies to cardiac surgeons and their patients,” cardiac surgery biz medical affairs VP Dr. Brian Duncan said in a press release.

LivaNova said that clinical data from trials of the valve showed that its use resulted in reduced procedure time, decreased postoperative complications and shorter hospital stays. The valve can be used in traditional open surgery as well as minimally invasive surgical approaches.

Earlier this week, LivaNova said it won expanded CE Mark approval in the European Union for its Vagus Nerve Stimulation Therapy systems, now labeled as safe for 1.5T and 3T magnetic resonance imaging scans.

The post LivaNova wins CMS NTAP reimbursement for Perceval aortic valve appeared first on MassDevice.

from MassDevice http://ift.tt/2weZDqE